LAS VEGAS, Jan. 26, 2026 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced its participation in the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium, held January 25-27, 2026, in Igls, Austria. As a leader in immunosuppression-free cell therapy solutions, Avant is actively evaluating advanced cells for potential application in a diabetes therapy at this premier European event.
This excerpt is quoted from the original release. Read the full announcement on PRNewsWire.
Brief Summary
Avant Technologies, Inc. (OTCQB: AVAI) is poised to make significant advancements in diabetes treatment, showcased at the 15th Annual EPITA Symposium held in Igls, Austria. The company specializes in innovative cell-based therapies particularly targeting diabetes and related disorders.
- Participation in a prestigious European symposium
- Focus on immunosuppression-free therapy solutions
- Evaluation of advanced cells for diabetes treatment
- Engagement with leading industry experts
- Potential market impact for innovative health solutions
Why it matters: Avant’s participation at EPITA suggests increasing momentum and recognition in the biopharmaceutical sector, highlighting its commitment to cutting-edge diabetes therapies.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by PRNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.